Patents and other immaterial rights
The company’s immaterial rights are mainly protected by patents and applications of the same. Submitted patent applications provides protection equivalent to a patent given that it is granted at a later time. Xspray’s patent portfolio consists of five patent families, containing both approved patents as well as patent applications. The granted patents provides protection from 2024 to 2033.
Xspray conducts an active and thorough patent strategy which includes applying for patent protection on an international level relating to the company’s in-house/developed technology, inventions and improvements that are crucial for the development of the business. Xspray currently uses its own patented and patent applied technologies and products and is therefore not dependent on any external licencing.
In addition, as of April 2017, the company has 32 granted patents and 25 patent applications currently being processed. The patents and the applications are submitted in in commercially important regions and countries such as the United States, Canada, Europe, China and Japan. Xspray’s assessment, based on conducted analyses, is that the patent applications likely will be granted and provide protection for planned drug candidates. The company’s patent portfolio consists of the following:
1) A unique mouth-piece which enables manufacturing of HyNap-PKI products
2) A method for the manufacturing of PKI-hybrid nanoparticles
3) Assemblage patents for the different PKI-products